Shenzhen Huixin Bio Completes Tens-of-Millions RMB Angel Round Led by Kairui Ventures

VCBeat (WeChat: vcbeat) has learned that Shenzhen Huixin Lifetech Co., Ltd. (hereinafter referred to as “Huixin Lifetech”) recently announced the completion of its tens-of-millions-yuan angel financing round. This round was exclusively invested by CoWin Ventures, and the funds will be primarily used for the market launch of exosome purification products and the research and development of early cancer detection technologies.

Huixin Lifetech is committed to technological innovation in the fields of exosome purification and early cancer diagnosis using exosomes. By collaborating with multiple research institutions and leveraging its team’s extensive experience in the medical device sector, Huixin Lifetech has developed a novel automated, label-free exosome isolation and purification technology. This technology addresses the urgent need for standardization, high recovery rates, and high purity during exosome extraction. Building on this isolation platform, Huixin Lifetech will develop exosome-based detection technologies for early cancer diagnosis, aiming to launch tumor screening-related products and services within three years.

Mr. Yang Yijie, Co-founder and General Manager of Huixin Lifetech, stated, “We sincerely appreciate CoWin Ventures’ recognition of Huixin Lifetech’s development roadmap. We have remained dedicated to achieving high-purity exosome isolation and advancing their clinical diagnostic applications through technological innovation. This financing round will accelerate the optimization and upgrading of our existing technologies, as well as the mass production of our products, thereby providing advanced technical support for basic exosome research and clinical applications in China. Furthermore, as exosomes represent a focal point in liquid biopsy, Huixin Lifetech will contribute to the upgrading of China’s healthcare industry by developing exosome-based technologies for early cancer screening.”

Dr. Huang Xin, Managing Partner at CoWin Ventures, stated, “Exosomes hold vast application prospects; however, technical bottlenecks in extraction and purification continue to significantly constrain the robust development of the exosome industry. The separation and purification technology developed by Huixin Lifetech will advance the standardized isolation and purification of exosomes as well as progress in cancer detection. Huixin Lifetech’s product positioning and strategic layout align closely with CoWin Ventures’ investment direction and philosophy. We look forward to partnering with Huixin Lifetech to jointly accelerate the rapid development of China’s exosome-based medical sector in support of the Healthy China strategy.”

Mr. He Xun, an investor in Huixin Lifetech’s seed round, Founding President of the Shenzhen Life Science and Biotechnology Association, and President of the Guangdong Provincial Innovation Center for Small-Molecule New Drugs, stated: “It is gratifying to see Huixin Lifetech reap the rewards of its long-term accumulation and enter a fast lane of development, injecting new vitality into Shenzhen’s life science industry. The Huixin Lifetech team possesses robust capabilities in technological innovation and commercialization, with distinct technical advantages in the field of exosome isolation and purification. We look forward to Huixin Lifetech launching products for exosome-based cancer screening soon to meet clinical needs.”